Combined with a world-class team with over 250 years of combined GMP and pharmaceutical R&D experience, Cannasouth has cemented itself as a leader in the medicinal cannabis industry in New Zealand.
Our goal is to develop next-generation cannabinoid therapeutics to support human and animal health outcomes and improve their quality of life.
Cannasouth is proud to be a founding member of the New Zealand Medicinal Cannabis Council (NZMCC).
We are represented on the NZMCC Board by Kate Flynn, and we work closely with the NZMCC to help set quality standards for New Zealand patients, and to shape the future of medicinal cannabis in New Zealand.
Cannasouth is developing medicinal cannabinoid therapeutic products of the highest standard, using the best pharmaceutical quality ingredients and manufacturing techniques to create medicines unrivalled regarding cannabinoid purity, quality, and efficacy.
Cannasouth Cultivation is located on a beautiful, 45ha site in the Waikato heartland. On this site we have developed a state-of-the-art Controlled Environment Agriculture (CEA) sealed greenhouse facility. This approach enables us to produce Premium-Plus GACP/GMP pharmaceutical quality cannabis flower year-round at a highly competitive production cost while using significantly less energy than indoor cultivation operations.
Providing GMP certified medicines that are safe, traceable and effective is at the heart of Cannasouth. “Good Manufacturing Practice” is the globally recognised quality control system used in pharmaceutical product manufacturing.
The quality of the plant material is the pillar for the production of cannabis-based medicines. By producing our cannabis flower using the power of the sun while doing so in a strictly controlled growing environment, we can ensure our finished products will meet strict GMP quality standards and be free of contaminants.
Research and Science
Cannasouth conducts drug discovery, pharmacological bioavailability and drug delivery research programs that support the development of advanced cannabinoid medicines, targeting a broad range of health conditions that patients suffer from.